Production (Stage)
Citius Oncology, Inc.
CTOR
$1.43
-$0.0428-2.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.33M | 17.34M | 15.65M | 14.17M | 12.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.16M | 22.38M | 20.57M | 18.95M | 16.90M |
| Operating Income | -25.16M | -22.38M | -20.57M | -18.95M | -16.90M |
| Income Before Tax | -25.16M | -22.38M | -20.57M | -18.95M | -16.90M |
| Income Tax Expenses | 816.40K | 696.20K | 576.00K | 576.00K | 576.00K |
| Earnings from Continuing Operations | -25.98 | -23.08 | -21.15 | -19.52 | -17.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.98M | -23.08M | -21.15M | -19.52M | -17.48M |
| EBIT | -25.16M | -22.38M | -20.57M | -18.95M | -16.90M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.37 | -0.33 | -0.31 | -0.29 | -0.26 |
| Normalized Basic EPS | -0.22 | -0.20 | -0.19 | -0.18 | -0.16 |
| EPS Diluted | -0.37 | -0.33 | -0.31 | -0.29 | -0.26 |
| Normalized Diluted EPS | -0.22 | -0.20 | -0.19 | -0.18 | -0.16 |
| Average Basic Shares Outstanding | 280.32M | 276.27M | 272.21M | 270.00M | 270.00M |
| Average Diluted Shares Outstanding | 280.32M | 276.27M | 272.21M | 270.00M | 270.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |